Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma
Jason Luke, MD
Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.
The future of systemic therapy for patients with melanoma in the advanced stages is in combinations, explains Luke. Currently, the standard of care for many patients is PD-1 antibodies, but combinations will continue to show improvement.
Combinations are also showing improvement in the adjuvant setting. In the next 2 to 5 years, most patients will be receiving combinations, states Luke.